Lilly
Pursues targeted therapy
Eli Lilly has been
ranked as the one of the best companies to work for and it has been
consistently progressing at par with the market growth.
![](/IMG/369/46369/rank15.gif)
Eli Lilly and Company (India) Pvt Ltd is a 100 percent subsidiary of US
pharmaceutical major, Eli Lilly. In India, the company enjoys
formidable presence in diabetes, cardiology, women’s health,
oncology and critical care. The company derives around 60 percent of
its revenues from the diabetes segment. Some biotech products of the
company include Forteo (Teriparatide), Huminsulin (Human Insulin),
Humalog (Human Insulin analog), Byetta (Exenatide), Xigris (Drotrecogin
Alfa) and Humatrope (Somatropin).
The company clocked revenues of Rs 164 crore in the fiscal year 2008-09
as against Rs 137 crore in 2007-08, thereby clocking a growth rate of
10 percent over 2007-08, in line with the market growth as per ORG IMS.
Within the diabetes care segment, the analog segment registered the
highest growth compared to other insulin players. The company today
enjoys a share of approximately 20 percent in the overall insulin
market.
In September 2008, the company launched a line extension (100 mg
variant) of its premier anti-cancer agent Alimta (Pemetrexed). Moving
forward, the company remains focused on pursuing the targeted therapy
approach. Elaborating on it, Sandeep Gupta, managing
director, Eli Lilly India, said, “Development in research has
helped scientists identify specific molecular targets within individual
cells, thereby heralding an era of targeted therapy, a concept which
Lilly has embodied. This technique enables companies like Lilly to
tailor treatment options for individual patients based upon the
presence of these molecular targets. This eventually leads to improved
treatment procedures for patient.” This approach is clearly
aligned with the Lilly vision. A case in point is the recent launch of
Alimta in first line management of non-small cell lung cancer, but only
of the non-squamous type.
Lilly focuses on bringing best-in-class products through its own
research stable or via collaborations. In October 2008, Lilly and
Jubilant Organosys formed a 50:50 joint venture (JV) to develop
molecules in areas of oncology, diabetes and cardiovascular diseases.
Both companies agreed to invest Rs 37.69 crore over the next three
years in the JV. In the same vein, March 2009 saw Lilly enter into
another R&D alliance with Zydus Cadila, this time in the area
of cardiovascular research. While Zydus will work to discover and
develop potential molecules against a novel target, Lilly will provide
chemical starting points and expertise and feedback on toxicology and
ADME. The deal is reported to be worth Rs 1,413 crore.
The company was recently ranked ninth in the ‘Best Companies
to work for’ survey conducted by the BT-TNS-Mercer. With this
recognition the company earns the unique distinction of
becoming the only pharma company that entered the list. Commenting on
the recognition, Sandeep Gupta said, “This ranking is also a
reflection of our continuous employee engagement initiatives throughout
the year. We will continue to look at alliances and partnerships where
products and services synergistically complement each other,”
he added.